Over 79 lakh vaccine registrations on April 28, mostly of 18-44 age group: CoWIN chief RS Sharma

The CoWIN platform witnessed a traffic of 55,000 hits per second, Sharma said, adding that the system is "functioning as expected".

Moneycontrol News

April 28, 2021 / 09:50 PM IST

National Health Authority CEO RS Sharma (File Image)

Over 79 lakh registrations for COVID-19 vaccine were recorded on April 28, claimed National Health Authority chief executive officer (CEO) RS Sharma, who is also the chief of CoWIN (Covid Vaccine Intelligence Work) platform.

The vaccine registration, via the CoWIN platform and Aarogya Setu App, was opened up for the 18-44 age group on April 28, three days before the start of inoculation drive's third phase. According to Sharma, most of the registrations were recorded from this age group.

"There have been 79,65,720 registrations on Co-WIN today, most of these in the last three hours (16:00-19:00) and mostly of 18-44 age group. We have seen a traffic of 55,000 hits per second. System functioning as expected," the CoWIN app chief said.

His statement, on Twitter, came hours after both - CoWIN and Aarogya Setu app - crashed due to the massive online traffic. An array of netizens took to social media to claim that they were unable to access both the portals.

Also Read: Online registration mandatory for 18-44 age group, here's how to register

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show